vimarsana.com

Latest Breaking News On - Hers health - Page 1 : vimarsana.com

Haemonetics Banks on Growing Plasma Arm, Innovation - Hims & Hers Health (NYSE:HIMS), Haemonetics (NYSE:HAE)

Haemonetics (NYSE: HAE) has been gaining from business growth within Plasma, Hospital and Hemostasis Management. Its new launches also aid growth. The stock carries a Zacks Rank #1 (Strong Buy) currently.

Hims & Hers Health (NYSE:HIMS) Shares Up 5 8%

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) shot up 5.8% on Wednesday . The stock traded as high as $23.47 and last traded at $23.31. 3,429,492 shares were traded during mid-day trading, a decline of 50% from the average session volume of 6,837,543 shares. The stock had previously closed at $22.04. Analyst […]

Hims & Hers Health (NYSE:HIMS) Trading 5 7% Higher After Insider Buying Activity

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) rose 5.7% on Monday after an insider bought additional shares in the company. The stock traded as high as $22.10 and last traded at $21.97. Approximately 2,810,538 shares traded hands during mid-day trading, a decline of 59% from the average daily volume of 6,811,084 shares. […]

Hims & Hers Health (NYSE:HIMS) Shares Up 5 7% on Insider Buying Activity

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) rose 5.7% on Monday after an insider bought additional shares in the company. The company traded as high as $22.10 and last traded at $21.97. Approximately 2,810,538 shares changed hands during trading, a decline of 59% from the average daily volume of 6,811,084 […]

Capricor Advances in DMD Therapy With Positive Study Data - Hims & Hers Health (NYSE:HIMS), Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology firm focused on innovative therapies for rare diseases, has announced favorable three-year results from the ongoing HOPE-2 open-label extension (OLE) study on CAP-1002 for Duchenne muscular dystrophy.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.